As director of technology and venture development (physical sciences division), Fazila sets strategy for bridging early-stage medical device and physical sciences technologies to market. She is responsible for directing a staff of analysts and managers in all aspects of market analysis, new product development from idea to prototype validation phase, and selling commercially-promising new client technologies from across the division in Medical Devices, Healthcare IT, Materials, Electronics, Energy, Information and Communications.
Fazila’s notable projects while at MaRS Innovation include leading the ClevrU-NewMindsets M&A transaction on behalf of York University, co-directing the WaveCheck Indiegogo campaign (business development lead) on behalf of Sunnybrook Health Sciences Centre and Ryerson University, and leading a co-development partnership with a leading global ultrasound manufacturer for an ultrasound chemotherapy monitoring technology.
Prior to joining MI, Fazila gained 10 years of experience leading new technology development and commercialization for GE and Xerox within Nanotechnology, especially electronic devices, systems and related specialty materials. At GE’s Global Research headquarters, Fazila led initial program creation for GE’s Corporate Nanotechnology initiative.
She is an invited adviser for leading professional organizations in Canada and the United States, including Canadian Foundation for Innovation (CFI), Canadian Institutes of Health Research (CIHR) and the U.S. National Science Foundation.
Fazila holds a Ph.D. in Chemistry from the University of Wisconsin-Madison and a B.Sc. in Chemical Physics from the University of Toronto.
Industry Expertise (5)
Areas of Expertise (14)
University of Toronto: BSc, Chemical Physics 1994
University of Wisconsin-Madison: PhD, Chemistry 1999
Thesis Adviser A. B. Ellis, "I. Probing Polymer Adsorption Using An Emissive Semiconductor Substrate. II. Correlation Of Chemical Structure And Swelling Behaviour in N-Alkylacrylamide Hydrogels"
Media Appearances (3)
Drug researchers turn to crowdfunding as ‘lean times call for creative measures'
National Post print
Dr. Fazila Seker, co-director of the WaveCheck campaign, was also interviewed in the National Post in Tom Blackwell’s front-page article, “Drug researchers turn to crowdfunding as ‘lean times call for creative measures.” It describes the Dragojlovic-Lynd study, in which WaveCheck was included in the sampling of medical-related crowdfunding campaigns, and examines what it may portend about the future of crowdfunding medical research.
CBC's The World This Weekend radio
MaRS Innovation staff and WaveCheck Campaign Co-directors Dr. Fazila Seker and Elizabeth Monier-Williams spoke with the CBC's Colleen Ross about the process of crowdfunding WaveCheck's partner-based clinical studies on "The World This Weekend."
The radio segment, called "Crowdfunding Science," aired on January 25, 2014 and discussed the lack of funding researchers have access to for commercialization, making it harder to advance research that could be helping people in a variety of industries.
Reflections on healthcare crowdfunding: Does a project have to get fully funded to be a ‘success?’
MedCity News online
MaRS Innovation’s Dr. Fazila Seker and Elizabeth Monier-Williams spoke with Deanna Pogorelc of MedCity News about how to define success for campaigns crowdfunding for technologies and research related to the medical field.
The article, in MedCity News‘ Hot Topics section, questions whether a crowdfunding campaign needs to reach its funding goal to be deemed successful.
Seker and Monier-Williams completed an Indiegogo crowdfunding campaign in December for WaveCheck, a clinical technique developed to let women and men know if their breast cancer chemotherapy is working within weeks of beginning treatment instead of months later when treatment has already ended.